Afficher la notice abrégée

Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008-2015): A cross-national drug utilization study

dc.rights.licenseopenen_US
dc.contributor.authorIBANEZ, L.
dc.contributor.authorSABATE, M.
dc.contributor.authorVIDAL, X.
dc.contributor.authorBALLARIN, E.
dc.contributor.authorROTTENKOLBER, M.
dc.contributor.authorSCHMIEDL, S.
dc.contributor.authorHEEKE, A.
dc.contributor.authorHUERTA, C.
dc.contributor.authorMARTIN MERINO, E.
dc.contributor.authorMONTERO, D.
dc.contributor.authorLEON-MUNOZ, L. M.
dc.contributor.authorGASSE, C.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMOORE, Nicholas
dc.contributor.authorDROZ, C.
dc.contributor.authorLASSALLE, R.
dc.contributor.authorAAKJAER, M.
dc.contributor.authorANDERSEN, M.
dc.contributor.authorDE BRUIN, M. L.
dc.contributor.authorGROENWOLD, R.
dc.contributor.authorVAN DEN HAM, H. A.
dc.contributor.authorSOUVEREIN, P.
dc.contributor.authorKLUNGEL, O.
dc.contributor.authorGARDARSDOTTIR, H.
dc.date.accessioned2020-06-23T09:06:32Z
dc.date.available2020-06-23T09:06:32Z
dc.date.issued2019-11
dc.identifier.issn0306-5251en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/8101
dc.description.abstractEnAIMS: To estimate the incidence of direct oral anticoagulant drug (DOAC) use in patients with nonvalvular atrial fibrillation and to describe user and treatment characteristics in 8 European healthcare databases representing 6 European countries. METHODS: Longitudinal drug utilization study from January 2008 to December 2015. A common protocol approach was applied. Annual period incidences and direct standardisation by age and sex were performed. Dose adjustment related to change in age and by renal function as well as concomitant use of potentially interacting drugs were assessed. RESULTS: A total of 186 405 new DOAC users (age >/=18 years) were identified. Standardized incidences varied from 1.93-2.60 and 0.11-8.71 users/10 000 (2011-2015) for dabigatran and rivaroxaban, respectively, and from 0.01-8.12 users/10 000 (2012-2015) for apixaban. In 2015, the DOAC incidence ranged from 9 to 28/10 000 inhabitants in SIDIAP (Spain) and DNR (Denmark) respectively. There were differences in population coverage among the databases. Only 1 database includes the total reference population (DNR) while others are considered a population representative sample (CPRD, BIFAP, SIDIAP, EGB, Mondriaan). They also varied in the type of drug data source (administrative, clinical). Dose adjustment ranged from 4.6% in BIFAP (Spain) to 15.6% in EGB (France). Concomitant use of interacting drugs varied between 16.4% (SIDIAP) and 70.5% (EGB). Cardiovascular comorbidities ranged from 25.4% in Mondriaan (The Netherlands) to 82.9% in AOK Nordwest (Germany). CONCLUSION: Overall, apixaban and rivaroxaban increased its use during the study period while dabigatran decreased. There was variability in patient characteristics such as comorbidities, potentially interacting drugs and dose adjustment. (EMA/2015/27/PH).
dc.language.isoENen_US
dc.subject.enPharmacoEpi Drug
dc.title.enIncidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008-2015): A cross-national drug utilization study
dc.title.alternativeBr J Clin Pharmacolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1111/bcp.14071en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed31318059en_US
bordeaux.journalBritish Journal of Clinical Pharmacologyen_US
bordeaux.page2524-2539en_US
bordeaux.volume85en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue11en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03209890
hal.version1
hal.date.transferred2021-04-27T13:13:51Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=British%20Journal%20of%20Clinical%20Pharmacology&rft.date=2019-11&rft.volume=85&rft.issue=11&rft.spage=2524-2539&rft.epage=2524-2539&rft.eissn=0306-5251&rft.issn=0306-5251&rft.au=IBANEZ,%20L.&SABATE,%20M.&VIDAL,%20X.&BALLARIN,%20E.&ROTTENKOLBER,%20M.&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_bjcp_Ibanez_2019.pdf
Taille:
1.159Mo
Format:
PDF
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée